Protheragen, an ISO9001-certified provider of preclinical contract research and analytical services, has announced its comprehensive drug analysis solutions that integrate stability studies, impurity testing, and chemical-physical testing to support pharmaceutical development and quality assurance. The services are designed to address critical needs across the product lifecycle, from early development to regulatory submission and commercialization.
According to the company, pharmaceutical companies rely on rigorous testing to ensure product safety, efficacy, and compliance. Protheragen's integrated offerings aim to streamline drug development and strengthen quality assurance by combining stability studies and impurity testing capabilities. The drug analysis services encompass chemical-physical tests covering parameters such as relative density, melting point, optical rotation, viscosity, particle size and morphology, dissolution, disintegration, and oxygen/water vapor transmission rates. These analyses help ensure optimal drug formulation, compatibility, and bioavailability while providing insights into product performance under real-world conditions.
Complementing the chemical-physical tests, the impurity testing service targets a broad range of contaminants, including organic, inorganic, heavy metal, elemental, residual solvent, and genotoxic impurities. This service mitigates risks from manufacturing byproducts, environmental exposure, and degradation processes to uphold product purity and safety. The stability testing portfolio includes accelerated stability studies using elevated temperature and humidity to predict degradation pathways and shelf life, as well as real-time stability studies conducted over the recommended product lifespan to monitor long-term performance.
A key component of Protheragen's stability testing is forced degradation studies, which are critical for drug development and regulatory compliance. By exposing drug substances and formulations to extreme stressors such as heat (dry and wet), light (per ICH Guide Option 2), humidity, acid/base hydrolysis, and oxidation, the company identifies intrinsic stability characteristics and degradation pathways. Using advanced analytical instruments including LC-MS, GC-MS, NMR, HPLC, and dynamic light scattering, the team quantifies degradation levels, validates stability-indicating methods, and provides data-driven recommendations for formulation optimization to enhance product shelf life and stability.
Protheragen's services are distinguished by a commitment to technical excellence, regulatory compliance, and client-centricity. The company's team of experienced scientists brings deep expertise in pharmaceutical analysis and adherence to international guidelines, including ICH standards, ensuring studies meet high quality and regulatory requirements. With cutting-edge analytical technology and customized study designs tailored to each drug candidate's unique needs, Protheragen delivers accurate, reliable results within agreed timelines, enabling clients to make informed decisions promptly. The transparent service process—from initial consultation and project planning to analysis, reporting, and follow-up support—ensures clients remain fully engaged and informed at every stage.
Pharmaceutical organizations seeking to enhance their development workflows, meet regulatory obligations, or optimize product stability are encouraged to contact Protheragen to discuss their project requirements. The company promises to respond to inquiries within 2-4 working days, offering tailored solutions to support clients in achieving their pharmaceutical development goals.
